ANI Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- ANI Pharmaceuticals reported 3rd quarter 2026 total net revenues of $290.8 million, up 28% year over year, and adjusted EBITDA of $83.3 million, up 40%.
- Rare disease net revenues grew 36% year over year, while generics revenues were $104.5 million, up 11%.
- Cortrophin Gel net revenues were $138.7 million, up 36% year over year, but below expectations because specialty pharmacy capacity constraints and slower-than-expected enrollment-to-fulfillment conversion delayed patient starts.
- ILUVIEN net revenues were $22.3 million, up 34% year over year; adjusted non-GAAP diluted earnings per share were $2.70, compared with $2.04 in the prior-year period.
- ANI reported non-GAAP gross margin of 61.8%, unrestricted cash of $420.8 million, and year-to-date cash flow from operations of $198.8 million.
- ANI announced an offer to acquire Aegidus Therapeutics for total equity consideration of $560 million; the enterprise value is approximately $434 million net of $95 million in cash proceeds from the sale of Aegidus's pediatric rare disease priority review voucher.
- The all-cash transaction is expected to be funded with approximately $300 million of ANI cash and up to $300 million in debt under a new committed bridge financing facility with JPMorgan; closing is expected in late 2026 or early 2027, subject to customary conditions.
- Emcitate is the first and only approved treatment in the U.S. and EU for peripheral thyrotoxicosis associated with MCT8 deficiency; it became commercially available in the U.S. last week, and ANI cited potential annual peak sales of over $300 million in its approved indication.
- More than 100 U.S. patients have been genetically confirmed, approximately 60 are receiving Emcitate through an expanded access program, and nearly 300 patients globally are being treated through the U.S. expanded access program and global managed access program.
- ANI repurchased 275,000 shares for $20 million year to date at an average purchase price of approximately $72.54.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Sorry, thank you. Good day, everyone, and welcome to today's ANI Pharmaceuticals Inc. Third Quarter 2026 Earnings Results Conference Call. Please note this event is being recorded. After the speaker's prepared remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press the star key followed by one on your telephone keypad. If you would like to withdraw your question, please press star then number 2 on your telephone keypad. It is now my pleasure to turn the conference over to Irina Koffler.
Thank you, Keith. Welcome to ANI Pharmaceuticals Third Quarter 2026 Earnings Results Call. This is Irina Koffler, Investor Relations for ANI. With me on today's call are Nikhil Lalwani, President and Chief Executive Officer, Stephen Carey, Senior Vice President and Chief Financial Officer, Chris Mutz, Senior Vice President and Head of ANI's Rare Disease Business, and Mary Pao, Chief Medical Officer. Earlier this morning, on November 5, 2026, we released our results in the third quarter 2026 via a press release that is available on our website. This call is also available via webcast and is accompanied by a slide deck that can be accessed by going to the events section of the investors page of our website. During this call, we will also be discussing the terms and conditions of ANI's offer to acquire outstanding securities of Egetis Therapeutics, which ANI announced this morning.
Please refer to the transaction website at www.biopharma-offer.com and the eight-K filed by ANI this morning that includes further information about the offer, including important considerations for holders of Egetis securities in the United States. Before we begin, I would like to remind you that we will be making forward-looking statements and discussing certain non-GAAP measures. Forward-looking statements are subject to substantial risks and uncertainties, speak only to the call's original date, and we take no obligation to update or revise any of the statements. During this call, we will also refer to certain non-GAAP financial measures to describe our performance and have provided a reconciliation to the most directly comparable GAAP financial measures within the materials that accompany this call. The archived webcast will be available for one year on our website, anipharmaceuticals.com. Okay, turning to the agenda for today's call.
Nikhil will provide an overview of our corporate strategy and Q3 performance, followed by an overview of our offer to acquire Egetis Therapeutics. Mary will dive into more detail on MCT8 deficiency and EMCITATE's mechanism of action. Chris will discuss the commercial opportunity for EMCITATE and will also provide an update on our rare disease business. Lastly, Steve will discuss our Q3 financial results and 2026 guidance. With that, I'll turn the call over to Nikhil Lalwani.
Thank you, Irina. Good morning, everyone, and thank you for joining us. We are now on slide seven. At the start of 2026, we set out three strategic priorities designed to position ANI for long-term growth. These include, first, accelerating ANI's transformation into a leading rare disease company, second, driving continued excellence in generics R&D and operations, and third, executing a disciplined capital allocation strategy. At ANI, we take pride in our virtuous cycle of growth, in which our generics and brands business generate meaningful cash flows to support our rare disease business. We are making meaningful progress against each of these priorities, including with today's offer to acquire Egetis Therapeutics. Before we dive into the details regarding the Egetis offer, I want to talk you through our third quarter results at a high level and our updated guidance. Turning to slide eight. For the third quarter, we generated $290.8 million of total revenues for the overall business, up 28% year-over-year, and adjusted EBITDA of $83.3 million, up 40% year-over-year.
Rare disease net revenues grew 36% year-over-year, and we saw continued growth in generics, up 11% year-over-year. Moving to slide nine. While we delivered strong overall results on the top and bottom line, I want to address our Cortrophin performance. We have been clear that our goal for Cortrophin is to maximize its multi-year growth opportunity by building on the momentum in our existing specialties and by expanding our organization to capture the sizable and unique opportunity in acute gouty arthritis flares. In the third quarter, Cortrophin Gel net revenues came in lighter than we expected when we outlined guidance last quarter at $138.7 million. This was primarily driven by two factors.
First, for the gout expansion team, we had strong demand generation in the third quarter with a large funnel of new patient cases, which doubled compared to the second quarter, highlighting physician interest and a large volume of appropriate patients. The significant volume of new gout cases put pressure on our specialty pharmacy network capacity, impacting the amount of cases that were processed for gout and also for our existing specialties of neurology, nephrology, rheumatology, ophthalmology, and pulmonology. Secondly, we increased our new prescriber base in the gout expansion by 67% compared to prior quarter. The primary care and podiatrist offices, naive to ACTH, are ramping up their capabilities in navigating the Cortrophin enrollment to fulfillment process. This ramp has taken a bit longer than we had anticipated.
This dynamic, coupled with the impact to our specialty pharmacy network capacity that I just mentioned, resulted in longer-than-expected conversion of new gout cases to patients on therapy. Chris will walk you through the significant steps we have already taken to address these dynamics. This is a key priority for us in the near term, and we are already seeing improvements in getting both gout and existing specialty patients onto therapy. That said, we are revising our 2026 Cortrophin Gel net revenue guidance to $480 million-$500 million, compared to $520 million-$540 million previously. Importantly, this represents year-over-year growth of over 40% at the midpoint on this revised guidance range. Nothing we have seen changes our conviction in the gout opportunity or in the strong multi-year growth potential of Cortrophin across indications. With respect to ILUVIEN, we demonstrated strong year-over-year revenue growth of 34%.
We plan to leverage the new SYNCHRONICITY study data presented at AAO in October, with a focus on the retina specialist community, to return ILUVIEN to growth across global markets. With three quarters under our belt, we are also tightening the guidance ranges for total company net revenue, adjusted non-GAAP EBITDA, and raising adjusted non-GAAP EPS. Our 2026 guidance reflects significant top and bottom line growth and the strength and diversification of our business, in particular, the continued outperformance of our generics business. Steve will walk you through the details later. As you can see on slide 10, year to date, we have launched 16 generics. We also continue to hold the number 2 position in overall CGT filings and approvals.
We are proud of our team's operational execution as it was able to seize multiple opportunities and benefit from strong market demand to deliver another outstanding quarter with generics revenue of $104.5 million, up 11% year-over-year. In terms of our third priority, disciplined capital allocation, we are continuing to invest in organic growth, most visibly in the gout expansion, and continuing to put a high single-digit percentage of generics revenues into generics R&D. We also repurchased $20 million in shares under the share repurchase program that was authorized by our board in May, reflecting our confidence in ANI's future. Steve will provide more details. Finally, today we also announced the offer to acquire Egetis Therapeutics. Turning to slide 11. Throughout the year, we have said that we are actively evaluating opportunities to expand our rare disease business, with a focus on attractive commercial stage or near commercial assets with durable IP that leverage our organizational capabilities.
Egetis meets each of these objectives. First and foremost, this transaction builds on our mission of serving patients, improving lives, which is really at the core of everything we do at ANI. We have followed the Egetis team closely, and we have been deeply impressed by their commitment to patients with MCT8 deficiency and to the families who care for them. This is a devastating condition. Children are born with it, families provide around-the-clock care, and until very recently, there was no approved treatment.
As we bring Egetis into ANI, our commitment is to honor that work to ensure that the patients and caregivers have the support they need to access the first and only approved treatment for MCT8 deficiency. Second, it expands the scope and scale of our rare disease business, broadening our commercial footprint into an additional rare disease call point with a product that has the potential to generate annual peak sales of over $300 million in its approved indication. Third, it has a new durable growth driver, EMCITATE. EMCITATE is the first and only approved treatment in the E.U. and U.S. for peripheral thyrotoxicosis associated with MCT8 deficiency. This is a rare disease, impacting more than 1,000 patients in the U.S. alone, and we will endeavor to facilitate patient diagnosis and bring this therapeutic to the appropriate patients in need.
Fourth, it leverages our resources and existing rare disease expertise and infrastructure to support EMCITATE's commercial launch. Our commercial organization brings deep rare disease experience, along with patient support, market access, and specialty pharmacy capabilities that we have built over the past five years with CORTROPHIN and ILUVIEN. We believe we can leverage our resources and capabilities to maximize the reach and impact of EMCITATE in one of the most underserved patient communities. Fifth, it strengthens our R&D capabilities, adding additional development and regulatory expertise in rare disease, along with a potential pipeline opportunity for EMCITATE in RTHβ, a separate rare indication. Finally, it diversifies our revenue base and enhances our long-term growth and profitability profile. Turning to slide 12, EMCITATE represents an ideal product to add to our portfolio. Mary will speak to the disease in more detail shortly.
EMCITATE was approved in Europe in February 2025 and in the U.S. in September 2026. EMCITATE became commercially available in the U.S. last week on October 27th. We estimate that approximately one in 70,000 males are impacted by MCT8 deficiency globally. Today, more than 100 U.S. patients have been genetically confirmed, and approximately 60 U.S. patients are already receiving EMCITATE through an Expanded Access Program, or EAP. This EAP gives us a clear starting point for the U.S. launch, with a significant opportunity to identify, diagnose, and treat additional appropriate patients over time. EMCITATE has durable growth runway supported by new chemical entity exclusivity, orphan drug exclusivity in both the U.S. and the E.U., and an Orange Book-listed patent extending into mid-2045.
We believe we have put forward an attractive offer that allows Egetis shareholders to realize the forward-looking value of EMCITATE, and we are pleased with the unanimous support we have received from the Egetis board of directors and significant shareholders controlling approximately 42% of shares. Slide 13 outlines the financial terms. We are offering to acquire Egetis for a total equity consideration of $560 million. This represents an enterprise value of approximately $434 million, net of the $95 million in cash proceeds that Egetis has agreed to receive from the sale of its Rare Pediatric Disease Priority Review Voucher, which was announced yesterday. This is an all-cash deal, and we will fund it through a combination of existing cash on hand and up to $300 million in debt, supported by new committed bridge financing facility from J.P. Morgan. Upon closing of the deal, we expect trailing 12-month pro forma net leverage to be approximately 2.7x.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
